| Patrick Park Patten, MD | |
|
2451 University Hospital Drive, Mastin 102, Mobile, AL 36617-2238 | |
| (251) 470-5890 | |
| (251) 471-7925 |
| Full Name | Patrick Park Patten |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 14 Years |
| Location | 2451 University Hospital Drive, Mobile, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1063731628 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0204X | Radiology - Vascular & Interventional Radiology | 34203 (Alabama) | Primary |
| 207Q00000X | Family Medicine | MD.205469 (Louisiana) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Singing River Health System | Pascagoula, MS | Hospital |
| Garden Park Medical Center | Gulfport, MS | Hospital |
| Memorial Hospital At Gulfport | Gulfport, MS | Hospital |
| Usa Health University Hospital | Mobile, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Usa Health Physician Billing Services Llc | 9931436912 | 266 |
| Smb Radiology Pa | 9234136060 | 20 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
| Entity Name | University Of South Alabama |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992746838 PECOS PAC ID: 3072425149 Enrollment ID: O20040115000773 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
| Entity Name | Usa Health Physician Billing Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720645468 PECOS PAC ID: 9931436912 Enrollment ID: O20190814000827 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
| Entity Name | Usa Health Physician Billing Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1871150508 PECOS PAC ID: 9931436912 Enrollment ID: O20200125000134 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
| Entity Name | Singing River Radiology Group, Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1396762209 PECOS PAC ID: 6204847064 Enrollment ID: O20200417002912 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patrick Park Patten, MD Po Box 40480, Mobile, AL 36640-0480 Ph: (251) 434-3626 | Patrick Park Patten, MD 2451 University Hospital Drive, Mastin 102, Mobile, AL 36617-2238 Ph: (251) 470-5890 |
News Archive
Ranbaxy Laboratories Inc. (RLI), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), today announced today that the U.S. Food and Drug Administration (FDA) has approved Absorica, a novel, patented brand formulation of the acne medication isotretinoin, for the treatment of severe recalcitrant nodular acne.
Women who developed type 1 diabetes before the age of ten years die an average of nearly 18 years earlier than women who do not have diabetes.
With an increasingly aging prison population, end-of-life care for inmates is becoming a more prominent issue, according to Penn State nursing researchers. End-of-life - EOL - care can be complicated, no matter who the patient is, but can be especially challenging for those behind bars.
According to a study conducted in Finland, the risk of ADHD was 34 percent higher in children whose mother had a vitamin D deficiency during pregnancy than in those children whose mother's vitamin D level was sufficient during the first and second trimesters.
ChemoCentryx, Inc., today announced that it reported positive Phase I results for its novel drug candidate CCX354 at the Annual European Congress of Rheumatology (EULAR). CCX354 is the Company's orally-active small molecule drug candidate designed to specifically target the CCR1 chemokine receptor for the treatment of patients with rheumatoid arthritis (RA).
› Verified 5 days ago
Dr. Jeston Taylor Smith, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Circle, Mobile, AL 36607 Phone: 251-435-2400 | |
Frank James Pitruzzello, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 6701 Airport Blvd Bldg B, Mobile, AL 36608 Phone: 251-633-1890 | |
Michael S Lawrence, M.D Radiology Medicare: Accepting Medicare Assignments Practice Location: 5 Mobile Infirmary Circle, Mobile, AL 36607 Phone: 251-435-2806 | |
Dr. Mathurika Jeyasingam, M.D. Radiology Medicare: Medicare Enrolled Practice Location: 2451 University Hospital Dr Rm 714, Mobile, AL 36617 Phone: 251-471-7866 Fax: 251-471-7882 | |
John P. Brannan Jr., MD Radiology Medicare: Not Enrolled in Medicare Practice Location: 2451 Fillingim St, Mobile, AL 36617 Phone: 251-471-7150 Fax: 251-471-7008 | |
Paul Richard Billeaud, Radiology Medicare: Accepting Medicare Assignments Practice Location: 2451 Fillingim St, Mastin 315, Mobile, AL 36617 Phone: 251-471-7866 |